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ABSTRACT
ELK-1 is a transcription factor involved in ERK-
induced cellular proliferation. Here, we show that its
transcriptional activity is modulated by ubiquitina-
tion at lysine 35 (K35). The level of ubiquitinated ELK-
1 rises in mitogen-deprived cells and falls upon mi-
togen stimulation or oncogene expression. Ectopic
expression of USP17, a cell cycle-dependent deu-
biquitinase, decreases ELK-1 ubiquitination and up-
regulates ELK-1 target-genes with a concomitant in-
crease in cyclin D1 expression. In contrast, USP17
depletion attenuates ELK-1-dependent gene expres-
sion and slows cell proliferation. The reduced rate of
proliferation upon USP17 depletion appears to be a
direct effect of ELK-1 ubiquitination because it is res-
cued by an ELK-1(K35R) mutant refractory to ubiqui-
tination. Overall, our results show that ubiquitination
of ELK-1 at K35, and its reversal by USP17, are im-
portant mechanisms in the regulation of nuclear ERK
signalling and cellular proliferation. Our findings will
be relevant for tumours that exhibit elevated USP17
expression and suggest a new target for intervention.
INTRODUCTION
The ETS transcription factor ELK-1 is acutely stimulated
bymitogens to establish a gene expression programme com-
mensurate with cell proliferation (1–4). ELK-1 is one of
three ternary complex factors (TCFs) (5–7) and binds with
serum response factor (SRF) to serum response elements
(SREs) in a subset of target gene promoters. In the mouse,
TCFs appear to be redundant (8–10), but this arrangement
is not conserved because in other chordates depletion of
a single TCF gene causes profound developmental defects
(2,11–14).
Latent, nuclear ELK-1 acquires activity upon phos-
phorylation by MAPKs and deSUMOylation by PIASx
(15–18). Target gene activation by phospho-ELK-1 in-
volves recruitment of active ERK to chromatin (19), phos-
phorylation of mediator subunits including MED14 (20)
and, uniquely for ELK-1 among the TCFs, functional re-
liance on MED23 (21,22). In proliferating human ES cells
(hESCs), ELK-1 also locates to the promoters of differen-
tiation genes independently of ERK and is associated with
their repression (2).
Developmental regulators are subject tomultiple levels of
control. Mechanisms that attenuate key transcription fac-
tors include binding of specific repressor proteins (23), post-
translational modifications (24), nuclear export (25), prote-
olytic cleavage (26) and proteasomal degradation (27). The
ubiquitin–proteasome system (UPS) is known to influence
levels of ELK-1, in particular the neuronal-specific isoform
sELK, which is rapidly degraded in non-neuronal cells due
to activation of a cryptic degron (28,29).
Here, we report a new mode of ELK-1 regulation in-
volving its reversible ubiquitination. Mono-ubiquitin or
low molecular weight ubiquitin species are conjugated to
the ETS domain of ELK-1, predominantly to lysine 35
(K35). For convenience, we refer hereafter to these ELK-
1-ubiquitin conjugates collectively as mono-ubiquitinated
ELK-1 (ELK-mUBQ). Inmitogen-stimulated or oncogene-
expressing cells, i.e. when ERK activity is elevated, levels
of ELK-mUBQ decline. We show that ELK-1 is a client
of the ubiquitin-specific protease 17 (USP17) and that the
two proteins interact directly. When expressed ectopically
USP17 markedly decreases levels of ELK-mUBQ, aug-
ments ELK-1 activity and increases expression of ELK-1
target genes. Conversely, USP17 knockdown leads to the
accumulation of ELK-mUBQ and attenuates ELK-1 tran-
scriptional activity.
USP17 expression is cell-cycle regulated, but its elevated
expression is a hallmark of multiple cancers and has been
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linked to aggressive tumour phenotypes (30–32). We find
that USP17 depletion decreases cell proliferation and that
expression of an ELK-1(K35R) mutant partially rescues
this effect. Our data show that by reversing ELK-1 mono-
ubiquitination USP17 augments transcriptional responses
to ERK signalling that promote cell proliferation, events
that are central to malignant cell growth.
MATERIALS AND METHODS
Cell culture and extract preparation
HEK293, HEK293T and HeLa cells were grown in Dul-
becco’s MEM (low glucose) supplemented with 10% foetal
calf serum (FCS), 2 mM L-glutamine, 100 Uml−1 penicillin
and 100 g ml−1 streptomycin. DU145 cells were grown
in Dulbecco’s MEM (high glucose) with the same supple-
ments. Whole cell extracts (WCEs) were prepared in a mod-
ified RIPA buffer; HeLa nuclear extracts were prepared as
described earlier (19).
Plasmids and DNA transfection
Plasmids and sources are listed in the Supplementary
Experimental Procedures. Calcium phosphate/DNA co-
precipitation was used to transfect HEK293/T cells, and
PEI or LT1 (Mirus) was used to transfect HeLa cells.
Ubiquitination assays
Cells were lysed in buffer containing 6M guanidinium–HCl
and protein–ubiquitin conjugates were captured by immo-
bilized metal affinity chromatography (IMAC) on Nickel-
Agarose beads (Qiagen) and washed in 8 M urea. After re-
lease from the beads conjugates were resolved by sodium
dodecylsulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) and detected by immunoblotting. The antibodies
used are listed in Supplementary Experimental Procedures.
In vitro ubiquitination assays were performed as de-
scribed elsewhere (33). Briefly, 35S-labelled ELK-1 was gen-
erated by cell-free expression using the coupled TNT retic-
ulocyte lysate system (Promega). After removal of unincor-
porated 35S-methionine by gel filtration (Micro-Spin, Bio-
Rad), radio-labelled ELK-1 was incubated with UBQ (10
g), rE1 (500 ng), rE2 (UBCH5; 500 ng), ATP (4 mM),
DTT (1 mM), ubiquitin aldehyde (5 M) and HeLa Nxt
(15–30 g) for 1 h at 30◦C. Reactions were resolved on 8%
SDS-PAGE gels, dried and visualized by phosphor-imaging
(Fujifilm).
Protein mass spectrometry
HEK293T cells transfected with a vector encoding His-
tagged ELK-1 were starved for 24 h or starved and stim-
ulated by addition of 15% FCS and tetradecanoylphorbol
acetate (TPA) (100 ng ml−1) before harvesting and protein
enrichment by denaturing IMAC.On-bead sampleswere re-
duced (50 mMdithiothreitol), alkylated (100 mM chloroac-
etamide) and digested with sequencing-grade trypsin (0.02
mg/ml). They were then submitted to tandem mass spec-
trometry (MS/MS) on an LTQ-Orbitrap-Velos spectrom-
eter with nano-flow liquid chromatography (LC). Identifi-
cation of peptides was conducted in data-dependent mode.
The raw data file obtained from each LC-MS/MS acqui-
sition was run against the Uniprot human database. Data
were analysed and di-gly modified peptides (+114) identi-
fied using Scaffold proteome software, combining Mascot
and X! tandem search engines to validate assigned spectra.
DNA-binding assays
Electrophoretic mobility shift assays (EMSAs) were per-
formed as described previously (29). Southwestern assays
were performed as described (34) with slight modifications.
Gene expression assays
For reporter assays, cells in 24-well plates were lysed
36 h post transfection in passive lysis buffer; firefly
and renilla luciferase expression were analysed with the
Stop and Glow system (Promega). Quantitative reverse
transcription-polymerase chain reaction (qRT-PCR) anal-
yses were performed as previously described (20). Gene-
specific primers and probes are listed in the Supplementary
Data.
Protein interaction assays
Co-immunoprecipitationswere performed as described pre-
viously (20). GST-USP17 fusions expressed in bacteria were
purified on glutathione agarose beads and incubated with
recombinant ELK-1 or ERK2. Bound protein complexes
were washed and resolved in SDS-PAGE for detection by
immunoblotting.
Intracellular protein distribution
Nuclear and cytosolic fractions of HEK293T cells trans-
fected with vectors for ELK-1 and control shRNA or
shUSP17#1 were isolated as described previously (29)
and resolved in SDS-PAGE for protein detection by im-
munoblotting. For high content imaging, HeLa cells were
transfected with vectors for ELK-1-GFP, ELK-1(R65)-
GFP and control shRNA or shUSP17#2, fixed and stained
with Hoechst H33342. Levels of ELK-1-GFP in nuclear
and cytosolic compartments were determined using a
Molecular Devices IX Ultra confocal plate reader and
MetaXpress 6 software. Ratios of cytosolic/total GFP fluo-
rescence were calculated for each GFP-positive cell and av-
eraged for all cells in an ROI. Data points represent average
ROI values (n = 48).
Cell proliferation assays
One day post transfection HEK293T cells were trypsinized,
counted and re-seeded into multiple 96-well plates at a den-
sity of 2 × 103 cells per well. Cell proliferation was moni-
tored daily using an MTT assay (35). Alternatively, trans-
fected cells were re-seeded into 24-well plates at a density
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of 1 × 104 cells per well and counted after 4 days using the
Moxi Z Mini Automated Cell Counter (Orflo).
Statistics
Reporter assay, qRT-PCR, cell counting and high content
imaging data are expressed as mean ± SEM. Statistical
analyses were performed with Student’s t-test. Proliferation
(MTT) assays were analysed using ANOVA with Tukey’s
multiple comparisons test. Significance is reported in fig-
ures by *P < 0.05, **P < 0.01, ***P < 0.001 and ****P <
0.0001.
RESULTS
ELK-1 is reversibly mono-ubiquitinated in proliferating cells
ELK-1 and its neuronal-specific, truncated isoform sELK
can be poly-ubiquitinated to mediate their degradation by
the proteasome (Supplementary Figure S1a) (29). However,
when immobilized metal affinity chromatography (IMAC)
was used in conjunction with his-tagged ubiquitin to har-
vest ubiquitinated proteins from HEK293T cells, the ELK-
1 species detected had single or lowmolecular weight (MW)
ubiquitin conjugates (Figure 1A, lane 3). These ELK-
mUBQ conjugates were unaffected by proteasome inhibi-
tion (Figure 1A, compare lanes 3 and 6). Populations of
endogenous ELK-mUBQ could also be isolated and were
enriched upon expression of an ubiquitin mutant (L73P)
that is refractory to deubiquitinase (DUB) activity (Figure
1B) (36). We also observed the formation of both poly- and
mono-ubiquitinated ELK-1 conjugates in cell-free ubiqui-
tination assays using HeLa nuclear extracts (Nxts) supple-
mented with recombinant E1 and E2 enzymes (33) (Figure
1C; see also Supplementary Figure S1b and c).
ELK-mUBQ conjugates were readily detected in serum-
starvedHeLa cells but their levels decreased followingmito-
gen stimulation (Figure 1D). Expression of a constitutively
active RAS or RAF allele starkly reduced ELK-mUBQ
levels (Figure 1E and Supplementary Figure S1d). The
MEK inhibitor U0126 attenuated mitogen-stimulated loss
of ELK-mUBQ (Figure 1F, compare lanes 7 and 8) whereas
the p38mapk inhibitor SB202190 did not (Figure 1F, com-
pare lanes 7 and 9). We also observed that ELK-1 mutants
lacking ERK docking motifs (D/FxLA) or key phos-
phorylation sites (S383, S389) underwent enhanced mono-
ubiquitination and that their mUBQ levels remained un-
changed after mitogen stimulation (Figure 1G). It seemed
plausible that ELK-mUBQ species might be intermedi-
ates in poly-ubiquitin chain formation. However, a lysine-
less ubiquitin (UBQ.K0) unable to build ubiquitin chains
formed a unitary ELK-mUBQ conjugate (Supplementary
Figure S1e), implying that ELK-mUBQ isoforms involve
a single lysine modified with a ubiquitin mono-, di- or
trimer. The ELK-1-UBQ.K0 conjugate was also lost upon
mitogen stimulation (Figure 1H, lanes 7–10), suggesting
that removal of mono-ubiquitin rather than chain exten-
sion and degradation is likely to account for ELK-mUBQ
loss. Together these data indicate that ELK-1 can be mono-
ubiquitinated in mitogen-starved cells and that the modifi-
cation is removed upon ERK signalling and ELK-1 phos-
phorylation.
ELK-1 is mono-ubiquitinated on K35 in the ETS domain
To identify ubiquitination sites in ELK-1, we used mutants
in which lysines had been substituted with arginines (Fig-
ure 2A). Elimination of lysines in the ETS domain abol-
ished mono-ubiquitination (Figure 2B), whereas removal
of lysines outside the ETS domain did not (Figure 2C).
Removal of all 10 lysines outside the ETS domain (R10)
caused significant ELK-1 accumulation (Figure 2D, lane
5). These data indicate that the mono-ubiquitination site(s)
resides in the ETS domain of ELK-1 and imply that one
or more C-terminal lysines might serve as sites of poly-
ubiquitination. In vitro ubiquitination assays also indicated
that ELK-1 was mono-ubiquitinated within the ETS do-
main (Figure 2E).
To map mono-ubiquitination site(s) within the ETS do-
main, we made multiple lysine substitutions in ELK-1 or
re-introduced lysines into theR18mutant (Figure 2F). Only
WT and R10 versions of ELK-1 were mono-ubiquitinated
and mutants R11 and NTR1 (Figure 2G, lanes 9 and 12)
identified K35 as the probable site of mono-ubiquitination.
We saw no evidence of R11 or NTR1 accumulation, unlike
mutant R10 (Figure 2G, lane 10), a further indication that
K35 is not a site of poly-ubiquitination. Mutant R12 was
also not modified, implying that K50 and/or K52 are also
required for ELK-1 mono-ubiquitination (see below).
To corroborate the functionalmapping data, we usedLC-
MS/MS to identify modified lysines directly by di-glycine
remnant mapping (Supplementary Figure S2) (37). We de-
tected ELK-1 peptides with a di-glycine stub onK35 inmul-
tiple experiments. K52 and K59 di-glycine remnants were
also detected but less frequently (Figure 2H). It is notewor-
thy that K52 andK59 both contact boundDNA (Figure 2I)
(38). We occasionally detected K48 ubiquitin linkages, sug-
gesting that ELK-mUBQ could include some short chain
isoforms. Together, the functional mapping and MS/MS
data identify K35 as the predominant mono-ubiquitination
site in ELK-1.
Ternary complex formation promotes ELK-1 mono-
ubiquitination
As K52 and K59 in the ETS domain of ELK-1 directly
contact bound DNA, we examined mono-ubiquitination in
relation to DNA binding. We compared SRF-dependent
binding to the CFOS SRE (39), direct binding to the high
affinity E74 site (40) and levels of mono-ubiquitination of
several ELK-1 lysine mutants and two previously charac-
terized DNA binding-deficient mutants (29). ELK-1-SM
(L158P/Y159A) is mutated in the B-domain and cannot
bind SRF but has an intact ETS domain allowing E74 bind-
ing; ELK-1-DM (R65A/Y66F) is mutated in the ETS do-
main and cannot bind DNA. In electrophoretic mobility
shift assays (EMSAs), the effects of mutations on SRF-
assisted and direct DNA binding were similar (Figure 3A
and B; Supplementary Figure S3) except for SM, which has
an intact ETS domain allowing E74 binding. Thus, for dif-
ferent reasons, neither ELK-1-SM nor ELK-1-DM formed
a ternary complex at the SRE (Figure 3A, lanes 4 and 5)
and although both contain all 18 lysine residues, neither
mutant was mono-ubiquitinated (Figure 3C, lanes 3 and
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Figure 1. ELK-1 is reversibly mono-ubiquitinated. (A) WCEs from HEK293 cells transfected with expression vectors for His.Tyg.UBQ and HA.ELK-1
were subjected to IMAC. Where indicated cells were treated with MG132 (10 M) for 8 h prior to harvest. Isolated proteins were analysed by SDS-
PAGE (7.5%) and immunoblotting with the antibodies indicated. Lower panels: WCEs analysed for ELK-1 expression. (B) WCEs from HEK293T cells
transfected with an expression vector for His.UBQ-WT or His.UBQ(L73P) were subjected to IMAC. Isolated proteins were analysed by SDS-PAGE (5–
20%) and immunoblotting with the antibodies indicated. Lower panels: WCEs analysed for protein expression as indicated. (C) In vitro ubiquitination
of 35S-labelled ELK-1 incubated with HeLa nuclear extract (Nxt) in the presence of recombinant E1, recombinant E2, UBQ and ubiquitin aldehyde
(UA) as indicated. Reactions were separated by SDS-PAGE (7.5%) and analysed by phosphor-imaging. Brackets indicate poly-ubiquitylated (pUBQ) and
mono-ubiquitylated (mUBQ) ELK-1 species. (D) HeLa cells were transfected with His.Tyg.UBQ andHA.ELK-1 as indicated before 24-h serum starvation
and stimulation with TPA as indicated. WCEs were subjected to IMAC. Bound proteins were analysed by SDS-PAGE (7.5%) and immunoblotting. Lower
panels:WCEs analysed for expression andERKactivation. (E)WCEs fromHEK293T cells transfectedwith expression vectors forHis.Tyg.UBQ,HA.ELK-
1 and V12-Ras, as indicated, were subjected to IMAC. Isolated proteins were analysed by SDS-PAGE (5–20%) and immunoblotting with the antibodies
indicated. Lower panels: WCEs analysed for protein expression and phosphorylation as indicated. (F) HeLa cells were transfected with His.Tyg.UBQ and
HA.ELK-1 as indicated, serum-starved for 24 h, pre-treated with U0126 (10 M) and/or SB202190 (5 M) and stimulated with TPA as indicated for 1
h. WCEs were processed and analysed as in panel (D). (G) HeLa cells were transfected with vectors for His.Tyg.UBQ and HA.ELK-1, ELK-1(S383/9A)
or ELK-1(D/FxLA) as indicated before 24-h serum starvation and stimulation with TPA for times indicated. WCEs were processed and analysed as in
panel (E). (H) HeLa cells were transfected with vectors for ELK-1 (no tag) and His.Tyg.UBQ or a lysine-less UBQ mutant (K0) as indicated before 24-h
serum starvation and stimulation with TPA for times indicated. WCEs were processed and analysed as in panel (D). In panels D, F, G and H, numbers
below upper immunoblots indicate relative band intensity as determined by densitometry.
4). This suggests that ternary complex formation may facil-
itate mono-ubiquitination of ELK-1. Consistent with this
idea, mono-ubiquitination of ELK-1 in our in vitro ubiq-
uitination system increased upon inclusion of an oligonu-
cleotide SRE duplex (Figure 3D). These data imply that
weak ternary complex formation associated with mutants
K50/52R and K59R (Figure 3A, lanes 7 and 8) may sup-
press their mono-ubiquitination (Figure 3C, lanes 6 and 7).
In contrast, K35R and K70R both form ternary complexes
with approximately 80% efficiency but only K70R is mono-
ubiquitinated (Figure 3C, lane 8), consistent with the iden-
tification of K35 as the predominant mono-ubiquitination
site in ELK-1.
Mono-ubiquitination of ELK-1 impairs DNA binding
Where lysine substitutions in the ELK-1ETS domain desta-
bilize DNA binding, ubiquitin conjugates could have a sim-
ilar effect. To test this notion, we used the his-tagged, DUB-
resistant ubiquitin mutant (L73P) (36) to increase the level
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Figure 2. ELK-1 is mono-ubiquitinated in the ETS domain, predominantly on lysine 35. (A) ELK-1 domain structure (ETS domain; B= SRF interaction;
S = SUMO consensus sites; D = MAPK docking; C = transactivation domain; f = ERK docking) indicating lysine distribution. The matrix represents
lysines present in ELK-1mutants as green discs and arginine substitutions as open grey circles. (B–D)WCEs fromHEK293 cells transfected with expression
vectors for His.Tyg.UBQ and HA.ELK-1, or the mutants indicated were subjected to IMAC. Isolated proteins were analysed by SDS-PAGE (7.5%) and
immunoblotting with the antibodies indicated. Lower panels: WCEs analysed for ELK-1 expression. (E) 35S-labelled ELK-1 and mutants indicated were
incubated alone (C), with E1, E2, UBQ and UA but without Nxt (-E3) or with all components (F) as indicated. Reactions were separated by SDS-PAGE
(7.5%) and analysed by phosphor-imaging. Bracket indicates ELK-mUBQ species. (F) As in (A). (G)WCEs fromHEK293 cells transfected with expression
vectors for His.Tyg.UBQ and HA.ELK-1 or mutants indicated were processed and analysed as in (B–D). (H) ELK-1.His was isolated from HEK293T
lysates by IMAC, subjected to tryptic digestion on beads and LC-MS/MS analysis (see ‘Materials and methods’ section). Bars represent total spectral
counts for each peptide from six independent analyses. Peptide sequences are show above bars with di-gly remnant modified lysines (K+114) highlighted
in red. (I) Structure of ELK-1 ETS domain indicating ubiquitinated lysines (red) in relation to bound DNA (adapted from (38).
of ELK-mUBQ in HEK293T cells, which we sought to iso-
late by IMAC and test in EMSAs. However, post-IMAC
ELK-mUBQ samples consistently contained unmodified
ELK-1, which we put down to previously reported dimer
formation (29,41). To circumvent this problem, we iso-
lated similar amounts of ELK-1 and ELK-mUBQ from
lysates under native conditions and performed a southwest-
ern assay to compare their DNA binding in parallel. Af-
ter SDS-PAGE and transfer to membrane, successful re-
folding of immobilized protein was confirmed with recom-
binant ELK-1, which readily bound an E74 probe, whereas
binding to renatured ERK was absent (Figure 3E, lanes
1 and 3). Significantly, although ELK-1 and ELK-mUBQ
were present in almost equal amounts on the membrane
(lane 2′′), ELK-mUBQ bound approximately 4-fold less
E74 probe than ELK-1 (lanes 2 and 2′). This result suggests
that mono-ubiquitination of the ELK-1 ETS domain inter-
feres with DNA binding.
Absence of mono-ubiquitination potentiates ELK-1 tran-
scriptional activity
We used ELK-1 mutants to explore the potential impact
of mono-ubiquitination on ELK-1 transcriptional activ-
ity. In luciferase reporter assays, ELK-1 was activated ef-
ficiently (approximately 30-fold) with an active RAF-1 that
mimics mitogen signalling and this activation was blunted
by alanine substitutions at key ERK phosphorylation sites
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Figure 3. ELK-1 mono-ubiquitination requires ternary complex formation but blocks DNA binding. (A) HA.ELK-1 and mutant proteins indicated were
incubated with a radio-labelled SRE probe and recombinant coreSRF. Complexes were resolved by electrophoresis and visualized by phosphor-imaging.
Solid arrowheads indicate ELK-1/E74 complexes; SS indicates super-shift obtained with anti-HA antibody (lane 2). Histogram (below) shows densito-
metric analysis of ELK-1/DNA complexes (solid arrows) in lanes 3–9 with ELK-1 set at 100%. (B) As in (A) except that complexes were formed with a
radio-labelled E74 probe; open arrowhead indicates non-specific band seen in WCE from control cells (lane 1). (C) WCEs from HEK293 cells transfected
with expression vectors for His.Tyg.UBQ and HA.ELK-1 or mutants indicated were subjected to IMAC. Isolated proteins were analysed by SDS-PAGE
(7.5%) and immunoblotting with an anti-HA antibody. Lower panel: WCEs analysed for ELK-1 expression. (D) 35S-labelled ELK-1 was incubated alone
(lane 1), with E1, E2, UBQ andUA (lanes 2–5) and with or without Nxt and an SRE oligonucleotide duplex as indicated. Reactions were separated by SDS-
PAGE (7.5%) and analysed by phosphor imaging. Bracket indicates ELK-mUBQ species. Histogram (right) shows densitometry of mono-ubiquitinated
species in lanes 2–5 with lane 2 set at 100%. (E) Lysate from HEK293T cells transfected with expression vectors for His.UBQ(L73P) and HA.ELK-1 was
subjected to IMAC. Recombinant ELK-1, ERK2 (Supplementary Figure S5) and IMAC samples were separated by SDS-PAGE (5–20%) transferred to
nitrocellulose, renatured and incubated with radio-labelled E74 probe. Lane 2′ shows longer exposure of lane 2. ELK-1 and ELK-mUBQ presence in
IMAC sample was confirmed by immunoblotting with anti-HA antibody (lane 2”).
[ELK-1(3A)]. The transcriptional activity of ELK-1(K35R)
(i.e. mutant NTR1) was significantly elevated over ELK-
1 (Figure 4A), whereas ELK-1(K70R), with SRE bind-
ing comparable to ELK-1(K35R) but normal levels of
mono-ubiquitination (see Figure 3A–D), showed no change
in activity. Mutants ELK-1(K50/52R) and ELK-1(K59R)
were not evaluated because of their severely impaired
ternary complex formation (see Figure 3A). ELK-1 mono-
ubiquitination also affected endogenous gene expression. In
cells transfected with an oestrogen-inducible active RAF-
1 (RAF-ER) (42), estradiol stimulated significantly higher
expression of CFOS, an established ELK-1 target gene,
when ELK-1(K35R) was expressed instead of ELK-1 (Fig-
ure 4B). These findings suggest thatmono-ubiquitination of
K35 decreases the transcriptional activity of ELK-1, most
likely by destabilizing DNA binding.
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Figure 4. USP17 reverses mono-ubiquitination to augment ELK-1 transcriptional activity. (A) HEK293T cells were transfected with SRE-Fluc and control
Rluc reporters, HA.ELK-1 or the mutants indicated and RAF259D (+) or vector control (-). After 48 h, cells were harvested and luciferase expression was
analysed. Inset showsELK-1 expression.Results are from three biological repeats and each performed in triplicate. (B)HEK293T cells were transfectedwith
vectors for HA.ELK-1 or ELK-1(K35R) and BXB-ER, an oestrogen-inducible, active RAF-1. Cells were serum starved for 24 h before stimulation with
estradiol (2 M) or mock treatment. After 2 h, RNAwas prepared for analysis by qRT-PCR. Results are from three biological repeats and each performed
in triplicate. (C) HEK293T cells were transfected with vectors for WT or catalytically inactive DUBs, in which the catalytic cysteine is substituted with
serine (C>S) or alanine (C>A), as indicated. RNAwas isolated after 48 h and analysed by qRT-PCR.CFOSmRNA levels are normalized toGAPDH and
represent means from three independent experiments, each assayed in triplicate. (D) WCEs from HEK293T cells transfected with expression vectors for
His.Tyg.UBQ, HA.ELK-1 and active or inactive DUBs as indicated were subjected to IMAC. Isolated proteins were analysed by SDS-PAGE (5–20%) and
immunoblotting. Lower panels: WCEs analysed for DUB and ELK-1 expression with antibodies indicated (left). (E) HEK293T cells were transfected with
USP17 sh#1 and sh#2 vectors or vector control as indicated. USP17 levels were determined by SDS-PAGE (5–20%) and immunoblotting. (F) HEK293T
cells were transfected with SRE-Fluc and control Rluc reporters, HA.ELK-1, the shRNA vectors indicated and RAF259D (+) or vector control (−).
After 48 h, cells were harvested and luciferase expression was analysed. Results are from three biological repeats and each performed in triplicate. (G
and H) HEK293T cells were transfected with shRNA vectors for USP17 or vector control as indicated. After 48 h, RNA was prepared and CFOS and
EGR1 mRNA were analysed by qRT-PCR. Levels are presented as fold ratios to GAPDH with controls normalized to 1 and represent means from four
independent experiments, each assayed in triplicate. (I) WCEs from HEK293T cells transfected with expression vectors for His.Tyg.UBQ, HA.ELK-1 and
control or USP17 shRNA vector as indicated were incubated either in full medium, serum-starved for 24 h or starved and stimulated with TPA for 40
min. WCEs were subjected to IMAC and isolated proteins were analysed by SDS-PAGE (5–20%) and immunoblotting with an anti-HA antibody. Lower
panels: WCEs analysed for ELK-1 expression and phosphorylation. All graphs show significance as defined in Materials and Methods.
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/advance-article-abstract/doi/10.1093/nar/gkz166/5373032 by U
niversity of N
ottingham
 user on 18 M
arch 2019
8 Nucleic Acids Research, 2019
USP17 (DUB-3) de-ubiquitinates ELK-1 to up-regulate tar-
get gene expression
Ubiquitin conjugation is reversed by deubiquitinases
(DUBs) (43), so ectopic expression of a DUB with speci-
ficity for ELK-1 might increase ELK-1-dependent gene ex-
pression. Consideration of GO terms for all human DUBs
identified several candidates with profiles similar to ELK-1,
all of which belonged to the USP family of DUBs. Among
those tested, only USP17 significantly increased ELK-1 re-
porter activity, whereas its catalytically inactive counter-
part (C>S) had no effect (Supplementary Figure S4a). We
then assessed the effect of ectopic DUB expression on tran-
scription of the ELK-1 target gene CFOS. USP17 expres-
sion markedly increased endogenous CFOS mRNA levels
whereas catalytically inactive USP17 and other DUBs did
not (Figure 4C and Supplementary Figure S4b). In agree-
ment with these findings, USP17 expression caused the loss
of ELK-mUBQ from cells whereas levels were unaffected
by a catalytically inactive USP17 or other DUBs (Figure
4D). In complementary experiments, we used two previ-
ously characterized shRNA vectors to deplete USP17 from
HEK293T cells (44,45) (Figure 4E). As anticipated, USP17
depletion decreased ELK-1 reporter activity (Figure 4F),
and significant reductions inCFOS andEGR1mRNAwere
seen compared to control cells (Figure 4G and H). Fur-
thermore, USP17 depletion increased ELK-mUBQ levels in
serum-starved, normally growing and mitogen-stimulated
cells (Figure 4I). These data show that USP17 can de-
ubiquitinate ELK-mUBQ and increase the expression of
ELK-1 target genes.
USP17 interacts directly with ELK-1 and countermands
ELK-1 nuclear export
ELK-1 and USP17, when expressed ectopically, readily
co-immunoprecipitated from HEK293T cell lysates (Fig-
ure 5A and B). Endogenous ELK-1 and USP17 also co-
immunoprecipitated from DU145 prostate cancer cells, in
which USP17 expression is elevated (Figure 5C). Their in-
teraction appears to be direct because recombinant GST-
USP17 bound to ELK-1 in vitro and deletion of the C-
terminal hyaluronan binding domains (46) fromUSP17 en-
hanced this interaction (Figure 5D and Supplementary Fig-
ure S5a). Analysis of binding to a series of ELK-1 deletion
mutants indicated that USP17 recognizes a motif located
between the ETS (A) and S domains, as ELK-1 deletions
lacking this region did not bind to USP17 (Figure 5E and
Supplementary Figure S5b).
Ubiquitination contributes to Mdm2-dependent nuclear
export of p53 (47,48), so we looked into whether mono-
ubiquitination levels affected the cellular distribution of
ELK-1.We found that USP17 knockdown, which increased
ELK-mUBQ levels (Figure 4I), caused a net redistribution
of ELK-1 from nucleus to cytoplasm (Figure 5F). Cell frac-
tionation also revealed that ELK-mUBQ was mostly cy-
tosolic (Supplementary Figure S5c). Furthermore, USP17
knockdown in HeLa cells increased the cytoplasmic dis-
tribution of an ELK-1-GFP fusion, in line with an ELK-
1(R65A)-GFP fusion that no longer binds to DNA (Figure
5G). Enhanced nuclear export of DNA-binding-defective
ELK-1 mutants had been observed previously (29). Col-
lectively, these data indicate that mono-ubiquitination sup-
presses ELK-1 transcriptional activity through impaired
DNA binding and consequent cytoplasmic redistribution
of ELK-mUBQ. Conversely, USP17 interacts directly with
ELK-1 to remove mUBQ conjugates, suppress nuclear ex-
port and augment ELK-1 transcriptional activity.
USP17 promotes ELK-1 target gene expression and cell pro-
liferation
The human USP17 gene is cell cycle regulated and its ex-
pression in G1 promotes G1-S progression (31). We found
that USP17 expression was stimulated by TPA and sup-
pressed by MEK inhibition (Figure 6A and B). Although
delayed with respect to expression of CFOS (Supplemen-
tary Figure S6), USP17 expression correlated with the ob-
served time frame of ELK-1 de-ubiquitination (see Fig-
ure 1D). Ectopic expression of USP17 substantially in-
creased mRNA levels of multiple ELK-1 target genes
(CFOS,EGR1, EGR2, IER2) but not control genes (MCL1,
VEGFA), whereas expression of USP22 had no such ef-
fect (Figure 6C–H). Increased levels of cyclin D1 (CNND1)
mRNA were also observed in cells transfected with USP17
but not with USP22 (Figure 6I). To confirm that this in-
crease in gene expression involved ELK-1, we used short
hairpin RNA (shRNA) to deplete endogenous ELK-1
and found that this significantly reduced USP17-mediated
CFOS expression (Figure 6J and K). These data are con-
sistent with the notion that USP17 promotes mitogen-
induced, ELK-1-dependent gene expression.
Depletion of USP17 has been shown to inhibit HeLa cell
proliferation (31). We confirmed this observation in MTT
assays (Supplementary Figure S7a). Similarly, we found
that USP17 knockdown inhibited HEK293T cell prolifer-
ation (Figure 7A). Furthermore, depletion of ELK-1 had
the same negative effect on HEK293T cell proliferation as
USP17 knockdown, confirming a positive regulatory role
for ELK-1 during proliferation in a ubiquitous human cell
model (Figure 7A and B; Supplementary Figure S7b).
We then tested whether the slower proliferation asso-
ciated with USP17 loss could be rescued by ELK-1. Ec-
topic expression of ELK-1 caused a significant reduction in
HEK293T proliferation, whereas ELK-1(K35R) appeared
to have little effect (Figure 7C and D). However, ELK-
1(K35R) partially rescued the decrease in proliferation as-
sociated with loss of USP17, whereas ELK-1 had no re-
medial effect. A significant rescue of USP17 knockdown
by ELK-1(K35R), but not ELK-1, was also seen indepen-
dently in cell counting assays (Figure 7E). Collectively, these
data indicate that mono-ubiquitination places a constraint
on ELK-1 activity that is removed in proliferating cells by
USP17. We conclude that ELK-1 is a bona fide client of
USP17 and that the positive impact of USP17 on cell pro-
liferation is mediated in part through de-ubiquitination of
ELK-1.
DISCUSSION
In response to mitogens, ELK-1 up-regulates a set of target
genes to promote and support cell proliferation (1–3).While
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Figure 5. USP17 acts directly onELK-1 to reversemono-ubiquitination and nuclear export. (A)WCEswere prepared fromHEK293T cells transfectedwith
vectors for HA.ELK-1 and/or catalytically inactive Myc.USP17. Immunoprecipitates were collected with control IgG, or Elk-1 antibody and analysed
by SDS-PAGE (5–20%) and immunoblotting as indicated. (B) As in (A) except that immunoprecipitates were collected with control IgG, or Myc (USP17)
antibody. (C) WCEs were prepared fromDU145 cells and immunoprecipitates were collected with control IgG or ELK-1 antibody and analysed by SDS-
PAGE (5–20%) and immunoblotting as indicated. (D) GST or GST-USP17 fusions (see diagram) on glutathione agarose beads were incubated with ELK-1
or ERK2. Input and bound proteins were analysed by SDS-PAGE (8%) and immunoblotting with an anti-His antibody. (E) GST or GST-USP17(H) on
glutathione agarose beads were incubated with ELK-1 deletion mutants (see diagram, key as in Figure 2A legend) or ERK2. Bound proteins and fusion
proteins on beads were analysed by SDS-PAGE (8%) and immunoblotting with an anti-His antibody. Red bar denotes region in ELK-1 required for USP17
interaction. (F) Nuclear (N) and cytosolic (C) fractions were prepared from HEK293T cells transfected with vectors for ELK-1.His and control or USP17
shRNA, submitted to IMAC and analysed by SDS-PAGE (5–20%) and immunoblotting with antibodies indicated. Graph shows C/N distribution ratios.
Results are from three biological repeats. (G) HeLa cells transfected with vectors for ELK-1-GFP, ELK-1(R65A)-GFP and control or USP17 shRNA,
as indicated, were fixed and analysed by high content confocal imaging. Data shown (n = 48) are from one of three experiments with similar, statistically
significant results (Student’s t-test); significance as defined in Materials and Methods. Inset panels show indicative GFP distribution.
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Figure 6. USP17 expression is mitogen inducible and up-regulates ELK-1 target genes. (A) HeLa cells were treated with TPA and MEK inhibitor U0126
as indicated. RNA was isolated and analysed by qRT-PCR for USP17 mRNA. Results are from four biological repeats and each performed in triplicate.
(B) Lysates from HeLa cells treated with TPA for 0, 30 and 60 min were analysed by SDS-PAGE (5–20%) and immunoblotting with antibodies indicated.
(C–I) HEK293T cells were transfected with increasing amounts of vector for USP17 or USP22. RNAwas isolated after 48 h and analysed by qRT-PCR for
CFOS (C), EGR1 (D), IER2 (E), EGR2 (F),MCL1 (G), VEGF (H) or CCND1 (I) mRNA. All mRNA levels were normalized to GAPDH and represent
means from three independent experiments, each assayed in triplicate. (J) HEK293T cells were transfected with Myc.USP17 and shRNA for ELK-1 as
indicated. RNA was isolated after 48 h, and CFOS mRNA was analysed by qRT-PCR. Levels are presented as fold ratio of CFOS/GAPDH with USP17
normalized to 1 and represent means from three independent experiments, each assayed in triplicate. (K) Lysates from HEK293T cells from (J) were
analysed by SDS-PAGE (5–20%) and immunoblotting with antibodies indicated. Significance is defined in Materials and Methods.
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Figure 7. USP17-mediated de-ubiquitination of ELK-mUBQ promotes cell proliferation. (A) HEK293T cells were transfected with shUSP17#1, shELK-1
or vector control as indicated. One day post transfection cells were seeded into 96-well plates and proliferation was assessed every 24 h byMTT assay. Data
are averages of three independent experiments in which each point is the average from four measurements; error bars show SEM. • = control v. USP17;
* = control v. ELK-1. (B) HEK293T cells were transfected with vector control or ELK-1 shRNA vector as indicated. ELK-1 levels were determined by
SDS-PAGE (5–20%) and immunoblotting. (C) As in (A) except that cells were transfected with vectors for shUSP17#1, ELK-1(WT), ELK-1(K35R) or
vector controls as indicated. Data are averages of three independent experiments; error bars show SEM: • =WT v. K35R; *= control v.WT;∧ = shUSP17
v. K35R/shUSP17. (D) HEK293T lysates from (c) were analysed by SDS-PAGE (5–20%) and immunoblotting with antibodies indicated. (E) As in (C)
except that cells were seeded into 24-well plates and counted on day 4. Data are averages of three independent experiments; error bars show SEM, with
control normalized to 1. Significance is defined in Materials and Methods. (F) Model for ELK-1 regulation involving phosphorylation (P) and removal of
mono-ubiquitin (U). SRE-binding promotes ELK-1 mono-ubiquitination and nuclear export. Mitogens stimulate ERK phosphorylation of ELK-1 and
de novo expression of USP17. USP17 reverses mono-ubiquitination to increase availability of active ELK-1 during G1. In concert with SRF, active ELK-1
stimulates expression of target genes to drive G1 progression and cell proliferation. Protein phosphatases (PP) can terminate ELK-1 activity.
the underlying role of ELK-1 phosphorylation has been
explored in depth, how other post-translational modifica-
tions affect ELK-1 function is less well understood. Here,
we have shown that mono-ubiquitination of K35 in ELK-1
suppresses its activity and thatmitogens stimulateUSP17 to
reverse this modification, thereby augmenting ELK-1 tran-
scriptional responses to ERK signalling. Our findings indi-
cate that USP17 acts on the ERK–ELK-1 axis to promote
cell proliferation and provide new mechanistic insight into
the contribution of USP17 to aggressive phenotypes asso-
ciated with diverse cancers (30–32).
Impact of mono-ubiquitination on ELK-1 function
Several lines of evidence confirmed the conjugation of
mono-ubiquitin to the amino-terminal ETS domain of
ELK-1. Mapping of modification sites using lysine substi-
tution mutants was ambiguous, due possibly to promiscu-
ity of the ubiquitin ligase(s) responsible. Moreover, scrutiny
of lysines involved in DNA binding (38) was complicated
because ELK-1mutants defective for SRF-mediatedDNA-
binding were refractory to mono-ubiquitination (Figure 3A
and C). Interestingly, ELK-1-DM and ELK-1-SMmutants
with a full complement of lysines were also not modified,
implying that ternary complex formation with SRF pro-
motes ELK-1 mono-ubiquitination. SRF present in HeLa
nuclear extracts may have contributed to the enhanced in
vitromono-ubiquitination of ELK-1 seen with SRE duplex
DNA. Ubiquitination of proteins associated with DNA is
known and exemplified by RNF8 acting in the DNA dam-
age response (49,50). Alternatively, shorter nuclear resi-
dence times associated with DNA binding-defective ELK-1
mutants may reduce their availability to a nuclear ubiquitin
E3 ligase (29).
LC-MS/MS-based di-glycine remnant mapping
(37) unequivocally identified K35 as the major mono-
ubiquitination site on ELK-1. K35 lies in 2 remote from
helix 3 (Figure 2I) and a K35R substitution is compatible
with ternary complex formation (Figure 3A and C). Minor
ubiquitination sites K52 and K59 lie within the 2/3
loop and 3 helix respectively and contact bound DNA
(38). Interestingly, ternary complex formation, which our
data suggest promotes mono-ubiquitination of ELK-1,
appears to be incompatible with modification at these two
sites. Conversely, mono-ubiquitination of ELK-1 appears
to impede DNA binding. K52R and K59R substitutions
disrupt DNA contacts (Figure 3A and B) and ubiquitina-
tion of either lysine would introduce steric interference.
How mono-ubiquitination of K35 might affect DNA
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binding is less readily apparent. Studies on Ets-1 revealed
that contacts between 1 of the ETS domain and two
vicinal Ets-1 helices allosterically inhibit DNA binding
(51). Conceivably, ubiquitin conjugation to K35 on this
surface of the ELK-1 ETS domain could result in a similar
allosteric effect, destabilizing DNA binding and facilitating
the ubiquitination of K52 and K59. Unequivocal evidence
for these effects will require studies on homogeneous
samples of ELK-mUBQ isoforms.
The increase in ELK-mUBQ and partial redistribution
of ELK-1 to the cytoplasm uponUSP17 depletion is consis-
tent with impairedDNAbinding, as noted earlier forDNA-
binding-defective ELK-1 mutants (29). However, it could
also reflect preferential engagement of the nuclear export
machinery with ELK-mUBQ. Alternatively, modification
of K52, which lies within a consensus nuclear localization
signal (52), may impair ELK-1 nuclear import. On balance,
mono-ubiquitination seems to diminish the transcriptional
activity of ELK-1 by impairing DNA binding and promot-
ing its cytoplasmic re-localization.
Contribution of de-ubiquitination to ELK-1-dependent gene
regulation
Approximately 95 mammalian DUBs serve to reverse the
actions of ubiquitin E3 ligases (43). Several DUBs are
known to include transcription regulators among their
client proteins: USP7 (HAUSP) de-ubiquitylates Gli pro-
teins to up-regulate gene expression downstream of Hedge-
hog signalling (53); USP9X de-ubiquitylates SMAD4 to
modulate TGF signalling (54). Relationships between
transcription factors and DUBs can be complex: for exam-
ple USP7, USP12, USP14, USP22 all appear to regulate the
stability and function of androgen receptor (AR) in prostate
cancer (55–58). As our search for an ELK-1 DUB focused
on enzymes whose biological characterization, tissue distri-
bution and intracellular location overlapped with those of
ELK-1, we cannot rule out the possibility that other DUBs
besides USP17 regulate ELK-1 activity.
ELK-1 and USP17 formed complexes in cells, they inter-
acted directly in vitro and USP17 expression caused ELK-
1 de-ubiquitination, correlating with increased transcrip-
tional activity, the specific expression of multiple ELK-
1 target genes and the downstream cell cycle regulator
CCND1 (cyclin D1) (59). Conversely, the higher ELK-
mUBQ levels observed uponUSP17 knockdown correlated
with reduced ELK-1 activity and target gene expression.
Depletion of ELK-1 substantially retarded HEK293T cell
proliferation, as did depletion of USP17, in line with pre-
vious reports (31), and expression of ELK-1(K35R), which
we showed to be hypo-modified and hyper-active, substan-
tially reversed the effect of USP17 depletion, linking modi-
fication of K35 in ELK-1 to observed cellular phenotypes.
Although an ELK-1(K35N) mutation has been observed in
an ovarian carcinoma (60), this is the first report to identify
mono-ubiquitination of K35 as a modulator of ELK-1 ac-
tivity and USP17 as the enzyme responsible for its removal.
Role of USP17 in cell proliferation and cancer
The USP17 gene (DUB3) has a highly variable copy
number within the human genome (61). USP17 expres-
sion is cytokine responsive, cell cycle regulated and linked
to G1/S progression (30–32). Other USP17 substrates
have been identified. Elevated USP17 expression has been
reported to promote de-ubiquitination of RCE1, inter-
fere with membrane localization of H-RAS and sup-
press MEK/ERK signalling (62). USP17 expression also
caused de-ubiquitination and stabilization of CDC25A, re-
sulting in replication stress and activation of the DNA
damage response (30). Furthermore, USP17 mediated de-
ubiquitination of H2AX and DEC1 has been shown to de-
lay DNA damage checkpoint recovery (44,63). These phe-
nomena correlate USP17 overexpression with stalled cell
proliferation.
USP17 is nonetheless strongly implicated in promot-
ing cell proliferation. In tumour-derived cells and biop-
sies, USP17 expression was found to be elevated (30,31).
In ovarian cancer and NSCLC, levels of USP17 expres-
sion correlated positively with tumour progression (32,64).
This role may be synergistic with CDC25A, because ele-
vated CDC25A levels in human cancer correlated positively
with USP17 activity, and USP17 was shown to cooperate
with H-RAS to transform NIH3T3 cells (30). USP17 also
acts to stabilize SNAIL1 in metastatic breast cancers in a
manner dependent on prior phosphorylation of USP17 by
G1 cyclins CDK4/6 (65). Thus, USP17 bears hallmarks of a
transforming oncogene and is able to promote tumour pro-
gression.
Activation of ELK-1 is contingent upon ERK phospho-
rylation at multiple sites in the C-terminal trans-activation
domain (5–7). Phosphorylation of ELK-1 may promote
USP17-mediated de-ubiquitination, because ELK-1 mu-
tants refractory to ERK phosphorylation resisted de-
ubiquitination in mitogen-stimulated cells. In the absence
of evidence for a phospho-recognition motif in USP17
clients, it is tempting to infer that phosphorylation-induced
conformational change promotes ELK-1 de-ubiquitination
(66). As we confirm, mitogens also promote USP17 ex-
pression in G1 (31). In murine ES cells (mESCs) Esrrb,
a component of the self-renewal machinery, up-regulates
the expression of Usp17 (67). Notably, down-regulation of
Usp17 in mESCs induced their spontaneous differentia-
tion (68). Likewise, human ESCs from which ELK-1 was
depleted ceased to proliferate and underwent differentia-
tion (2). USP17-mediated de-ubiquitination of ELK-1 may
therefore help to sustain ESC self-renewal as well as pro-
moting G1 progression.
Individual knockdowns of USP17 and ELK-1 both im-
pacted negatively on HEK293T cell proliferation. These ef-
fects were linked because expression of ELK-1(K35R) sub-
stantially rescued the loss of proliferation associated with
USP17 depletion. The effectiveness of ELK-1(K35R) in
these experiments is perhaps surprising given that ELK-1
is just one of several USP17 clients and, arguably, may be
functionally redundant to ELK-3 and ELK-4 (8–10). The
impact of USP17 acting on ELK-1 to augment ERK sig-
nalling is thus likely to vary in different cellular contexts.
Nonetheless, our findings uncover an important functional
relationship between USP17 and ELK-1 in its conserved
role as ERK responder and activator of mitogenic gene ex-
pression (Figure 7F). Indeed, the impact ofUSP17 onELK-
1 function may extend beyond its relationship with ERK,
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given the recent discovery of a physical and functional coop-
eration between ELK-1 and androgen receptor in advanced
prostate cancer (69,70). A next priority will be to identify
the ubiquitin E3 ligase(s) specifically responsible for mono-
ubiquitination of ELK-1.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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